Aids in the workup of suspected myeloproliferative neoplasms. Use to detect the JAK2 V617F mutation in peripheral blood or bone marrow.
Droplet Digital Polymerase Chain Reaction
DNA Isolation: Sun-Sat
New York DOH Approval Status
Whole blood or bone marrow: Lavender (EDTA), preferred. Also acceptable: Green (sodium heparin)
Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow: Do not freeze. Transport 3 mL bone marrow. (Min: 1 mL)
Plasma, serum, FFPE tissue blocks/slides, or fresh or frozen tissue, DNA extracted by a non-CLIA certified lab. Specimens collected in anticoagulants other than EDTA or sodium heparin. Clotted or grossly hemolyzed specimens.
Refrigerated: 7 days; Frozen: Unacceptable
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|3003752||JAK2 QNT, Source||31208-2|
|3003753||JAK2 V617F Percent Mutated Alleles||53761-3|
|3003754||JAK2 V617F Mutation by PCR||43399-5|
- BCR-ABL1 negative testing
- Classic BCR-ABL1-negative testing
- MPN JAK2
- mutant JAK2 V617F allelic burden